{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:02:44Z","timestamp":1788616964053,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.vaccine.2014.02.050","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T09:00:35Z","timestamp":1395046835000},"page":"2359-2363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children"],"prefix":"10.1016","volume":"32","author":[{"given":"Shousun C.","family":"Szu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith P.","family":"Klugman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.050_bib0005","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/649541","article-title":"Global trends in typhoid and paratyphoid fever","volume":"50","author":"Crump","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2014.02.050_bib0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2471\/BLT.06.039818","article-title":"A study of typhoid fever in five Asian countries: disease burden and implications for controls DOMI typhoid study group","volume":"86","author":"Ochai","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0015","unstructured":"Requirements for Vi polysaccharide typhoid vaccine. World Health Organization Technical Report Series. 1994; No. 840."},{"key":"10.1016\/j.vaccine.2014.02.050_bib0020","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJM198710293171801","article-title":"Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report one year after immunization","volume":"317","author":"Acharya","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0025","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(87)91316-X","article-title":"Protective activity of Vi capsular polysaccharide vaccine against typhoid fever","volume":"II","author":"Klugman","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0030","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJM200310023491423","article-title":"Persistent efficacy of Vi conjugates against typhoid fever in young children","volume":"349","author":"Lanh","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2014.02.050_bib0040","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate, a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Exp Rev Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0045","doi-asserted-by":"crossref","first-page":"6443","DOI":"10.1016\/j.vaccine.2011.06.006","article-title":"Coalition against Typhoid (CaT): a new, global initiative to advance typhoid vaccination","volume":"29","author":"Nelson","year":"2011","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.vaccine.2014.02.050_bib0050","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1016\/j.vaccine.2013.07.070","article-title":"Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5\u20137 September 2012","volume":"31","author":"Jones","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0055","first-page":"219","article-title":"Vaccine efficacy determination","volume":"14","author":"Broome","year":"1991","journal-title":"NIPH Ann"},{"issue":"3","key":"10.1016\/j.vaccine.2014.02.050_bib0060","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1365-2249.2003.02232.x","article-title":"Measurement and interpretation of pneumococcal IgG levels for clinical management","volume":"133","author":"Balmer","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.02.050_bib0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0264-410X(88)90175-2","article-title":"Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever","volume":"6","author":"Tacket","year":"1988","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2014.02.050_bib0070","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.vaccine.2013.02.006","article-title":"A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned","volume":"31","author":"Szu","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.02.050_bib0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0264-410X(98)00160-1","article-title":"Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization","volume":"17","author":"Keddy","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0264-410X(95)00186-5","article-title":"Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization","volume":"14","author":"Klugman","year":"1996","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2014.02.050_bib0085","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0264-410X(03)00025-2","article-title":"Correlates of immunity for pneumococcal conjugate vaccines","volume":"16","author":"Lee","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2014.02.050_bib0090","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00006454-199808000-00005","article-title":"Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine","volume":"17","author":"Sorensen","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.02.050_bib0095","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/infdis\/140.5.690","article-title":"Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization in infants and children","volume":"140","author":"Gold","year":"1979","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2014.02.050_bib0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2014.02.050_bib0105","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1128\/IAI.72.11.6586-6588.2004","article-title":"Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children","volume":"72","author":"Canh","year":"2004","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2014.02.050_bib0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"19","key":"10.1016\/j.vaccine.2014.02.050_bib0115","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2014.02.050_bib0120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T01:58:01Z","timestamp":1538791081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14002357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":24,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0264410X14002357"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}